Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-MICROBIO: Probiotics and FMT in T2D
NCT05076656Phase 1Completed
- Start
- Jun 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of lactobacillus fermentum + vitamin d3 and Fecal Microbiota Transplantation capsules in type 2 diabetes mellitus (T2DM) and obesity (3 arms). Primary endpoint: Homeostatic Model Assessment for Insulin Resistance at 12 weeks. Started Jun 2019; status: completed.
02
Drugs
lactobacillus fermentum + vitamin d3Fecal Microbiota Transplantation capsules
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05076656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076656.